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THE RELATION OF PREOPERATIVE COAGULATION FINDINGS 
TO DIAGNOSIS, BLOOD USAGE, AND SURVIVAL IN ADULT 
LIVER TRANSPLANTATION 
FRANKLIN A. BONTEMPO,l JESSICA H. LEWIS, DAVID H. VAN THIEL, JOEL A. SPERO, 
MARGARET V. RAGNI, PATRICIA BUTLER, LINDA ISRAEL, AND THOMAS E. STARZL 
The Department of Medicine and Surgery, University of Pittsburgh, and the Central Blood Bank of Pittsburgh, Pittsburgh, 
Pennsylvania, 15219 
. A group of 70 adults with end-stage liver dise'ase 
received 87 homologous liver transplants from 7/11/81 
and 7/11/83. The recipients fell into the following di-
agnostic categories: post necrotic cirrhosis (PNC) in 22, 
primary biliary cirrhosis (PBC) in 18, cancer or neopla-
sia (CA) in 11, sclerosing cholangitis (SC) in 8 and 
miscellaneous (MIS C) in 11. Survival for six months or 
longer was 46%: survival by group was PBC=67%, 
CA=55%, PNC=45%, SC=25%, and MISC=18%. Pre-
operative coagulation profiles were evaluated on 64 of 
the 70 first transplant patients by assigning a score 
derived from one point per abnormality in each of 8 
tests. Mean coagulation abnormality scores (CAS) were 
strikingly elevated in the PNC and MISC groups. Mean 
intraoperative blood product usage was 43 units of 
RBCs, 40 units of fresh frozen plasma (FFP), 21 units 
of platelets, and 9 bags of cryoprecipitate. Direct cor-
relations were found between CAS and RBC usage 
(+0.454, P=<.OOl), CAS, and survival of 6 months or 
longer (-0.281, P=<.02), and RBC usage and survival 
(-0.408, P=<.OOl). These findings indicate that the 
degree of coagulation abnormality and the type of liver 
disease may be predictive of intraoperative blood usage 
and survival in liver transplantation in adults. 
Liver transplantation has been used to treat patients with a 
wide variety of end-stage liver disorders (J -3). Better methods 
1 Address correspondence and reprint requests to: Franklin A. Bon-
tempo. M.D., Central Blood Bank of Pittsburgh, 812 Fifth Avenue, 
Pittsburgh, PA 1;'2J '1 
for the procurement, preservation, and transport of donor liv-
ers, improved and innovative surgical techniques, and the use 
of cyclosporine for immunosuppression have recently made this 
procedure feasible for an increasing number of patients. 
Liver disease in which the parenchyma is severely and exten-
sively damaged is frequently accompanied by clotting abnor-
malities and it may result in serious spontaneous (4) or post-
operative bleeding (5). Previously, in patients undergoing liver 
transplantation, the evaluation of preoperative parameters was 
sporadic and unsystematic (6-12). In this study preoperative 
coagulation studies have been ordered on most of the liver 
transplant candidates as an aid in diagnosis of the severity and 
type of liver disease. Data on blood product usage was correlated 
with preoperative coagulation abnormalities and survival in an 
attempt to predict which patients are at risk for massive bleed-
ing during transplantation. 
MATERIALS AND METHODS 
Patient categorization. Seventy adult liver transplant recipi-
ents whose first operation occurred between 7/11/81 and 7/11/ 
83 have been categorized into five major diagnostic groups. In 
an otherwise consecutive series, the first four adult transplants 
done in Pittsburgh were omitted because the donated livers 
were inadequately preserved; two other candidates were ex-
cluded because the operation was impossible-in one because 
of the thrombosed portal vein, and in the other because of 
absence of the hepatic artery consequent to trauma and pre-
vious surgical repair. As shown in Table 1., the most frequent 
p 
May, 1985 BONTEMPO E';' AL. 533 
TABLE 1. Categorization of patients 
Diagnosis No. F M Age range 
Postnecrotic cirrhosis (PNC) 22 8 14 18-48 
Primary biliary cirrhosis (PBC) 18 18 0 36-59 
Carcinoma/neoplasia (CA) 11 7 4 21-54 
Sclerosing cholangitis (Se) 8 2 6 17-45 
Miscellaneous (Mise) 11 3 8 25-47 
Totals 70 38 32 17-59 
type of liver disease was postnecrotic cirrhosis (PNC)2 with 22 
patients, five of whom had had hepatitis B, seven of whom had 
chronic active hepatitis (CAH), and the remaining ten of whom 
were being followed for hepatitis-presumably of the non-A, 
non-B type. The next most common category was primary 
biliary cirrhosis (PBC), which consisted of 18 female patients. 
Of the 11 patients in the cancer-neoplasia (CA) group, 7 suf-
fered from hepatoma-l of which followed tyrosinemia, two 
from cholangiocarcinoma, one from angiosarcoma, and one 
from mUltiple hepatic adenomas that had previously been par-
tially resected. Eight patients suffered from sclerosing cholan-
gitis (SC). In the miscellaneous category, there were four pa-
tients with fulminant hepatitis-one from gold toxicity, one 
from exposure to paint containing 2-nitropropane, and two 
following presumed non-A non-B hepatitis-two patients with 
C¥l antitrypsin deficiency (one with hemochromatosis), and one 
each with alcoholic cirrhosis plus postnecrotic cirrhosis, con-
genital biliary hypoplasia, secondary biliary cirrhosis (resulting 
from postoperative stricture), secondary biliary cholangiectasis, 
and venoocc1usive disease. 
Laboratory. Coagulation tests were performed using standard 
or previously described methods (13-15). Preoperative tests 
were performed on 64 of the 70 patients within three months 
of the operation. The standard coagulation profile included the 
eight tests listed below and assays for coagulation factors II, V, 
~ffI X, VIII, IX, XI, XII, and Fletcher (prekallikrein); bleeding 
time; platelet glass retention index; and platelet aggregation 
tests. In order to simplify the handling of coagulation data, a 
score, called the coagulation abnormality score, was derived for 
each patient by allowing one point for each abnormality in the 
following tests. To obviate any gray areas only the distinctly 
abnormal values given below were counted: 
Range 
PT 
APTT 
TT 
I 
Plat. C. 
AT-III 
FSP 
~sis 
Prothrombin time (sec) 
Act. partial thromboplastin 
time (sec) 
Thrombin time (sec) 
Fibrinogen (mg/dl) 
Platelet count X 103 / ~l 
Antithrombin III-U/mi 
Fibrinogen split products 
(ethanol gel (2-4+) and 
Thrombo-Wellcotest E~O 
ng/ml) 
Euglobulin lysis time (hr) 
Abnormal Normal 
13.5 or> 10.8-13.0 
36.0 or > 26-34 
20.0 or> 13-18 
149 or < 150-450 
149 or < 150-450 
70 or < 80-120 
+ 0 
2or< 4 
2 Abbreviations used in this article: CA, cancer or neoplasia; CAS, 
Coagulation abnormality scores; cryo, cryoprecipitate; FFP, fresh frozen 
plasma; MISC, miscellaneous; PBC, primary biliary cirrhosis; plat; 
platelets; PNC, postnecrotic cirrhosis; RBC, red blood cells' SC scle-
rosing cholangitis. ' , 
Operative techniques. The operative techniques have been 
described elsewhere (1-3). During a three-month period, 6/15/ 
82 to 9/6/82, heparin was used during 12 transplant procedures 
in nine patients. The heparin was used to prevent clotting while 
shunting blood from the operative area. Three operative deaths 
(25 %) occurred in the heparinized patients, in comparison with 
6 operative deaths in the other 75 liver transplants (8%). More 
recently a special polyvinylchloride tubing (ARGYLY; Sher-
wood Medical Industries, St. Louis, MO) coated with TDMAC/ 
heparin complex has been used for bypass. This coating inhibits 
clot formation without causing generalized heparinization. 
Pathological findings. Organs removed at the operation were 
weighed and examined for the presence or absence of any focal 
abnormalities and disorders of the vascular and biliary struc-
tures. They were then sectioned in l-cm slices and reexamined. 
After initial fixation in 10% formaldehyde, tissues were proc-
essed and embedded in paraffin, sectioned at P-~I and stained 
with hematoxylin and eosin, Massey trichome, and reticulin 
stains using. standard techniques. Tissue sections were then 
read blindly by two examiners and classified into cirrhotic and 
noncirrhotic groups, which were then subclassified according 
to whether the cirrhosis was postnecrotic. Following these 
determinations, and based upon the major gross and histologic 
fixtures of each case, a specific diagnostic and/or etiologic 
category was determined (Table 1). In each of primary biliary 
cirrhosis, the disease process was well advanced, in stage 3 or 
stage 4. Similarly, in each case of sclerosing cholangitis, the 
disease process was well advanced, and accompanied by cir-
rhotic changes. 
Statistical methods. Significance was determined by the 
Mann-Whitney test; correlations were obtained by the Spear-
man ranked test. 
RESULTS 
Survival. Thirty-two (46%) patients have survived at least 6 
months from the time·ofthe most recent liver transplant. Entry 
of survival date was closed 1/11/84, six and a half months after 
the first liver transplant in the last of the 70 recipients studied. 
Table 2 analyzes survival by disease category and date of last 
tr~nsplantI and it shows the number who survived compared 
With the number of operations done. The bottom line shows 
that survival was best in the PBC and CA groups, intermediate 
in ~kCI and worst in MISC and SC. Rather surprisingly, 
surVival was best in the earliest procedures, followed by a 
distinct drop during 1982 and then an increase in early 1983. 
As of 1/11/84, there were seven patients who had survived for 
more than 2 years, thirteen for 1-2 years, and twelve for 6 
months to 1 year. 
Causes of death. Of the 38 patients who died, four died after 
TABLE 2. Survival (as of 1/11/84) after last liver transplant by 
disease category and date of transplant 
Date of last liver transplant 
No. survived/No. performed 
% 
PNC PBC CA SC Mise Total 
7/11/81-12/31/81 3/6 1/1 1/2 1/1 1/1 7/11 64 
1/01/82- 6/30/82 1/5 3/4 2/4 0/0 0/1 6/14 43 
7/01/82-12/31/82 2/3 3/6 1/2 1/5 0/4 7/20 35 
1/01/83- 6/27/83 4/8 5/7 2/3 0/2 1/5 12/25 48 
Total 10/22 12/18 6/11 2/8 2/11 32/70 
% 45 67 55 25 18 46 
-
". 
.... -
., 
!i. 
" it il 
!~ 
D~ 
!~ 
" !i 
i j 
I 
I 
11 
11 
't 
> 
534 TRANSPLANTATION VoL 39, No.5 
200 days-two of recurrent disease, one of infection, and one 
from myocardial infarction. Eight patients died 50-200 days 
after the last transplant; four from rejection with or without 
sepsis, one from thrombosis of the graft, two from hemorrhage 
(one hepatic artery and one intrathoracic), and one from splenic 
rupture. Seventeen patients died 2-49 days after the operation. 
In eleven the major cause was infection, and in three it was 
rejection-although all probably had some degree of both. 
Aspergillosis was identified in four. Nine patients died during 
the operative period. 
Coagulation. Table 3 gives the mean CAS values for each 
patient group, listed in order of decreasing severity of coagula-
tion abnormalities. The standard deviations for CAS values in 
each group and the significance of the difference of the mean 
of each from the mean of the CA group, the group with the 
lowest CAS, is calculated. The P values for PNC and MISC 
are highly significant. 
Table 4 shows the number of patients in each group on whom 
preoperative coagulation profiles were performed, the mean 
value, and the percentage that was abnormal in each of the 
general coagulation tests. In the entire group (64) the thrombin 
time was the most frequently abnormal test, followed by AT-
III, APTT, and platelet count. 
Table 5 shows the mean values in factor assays for each 
patient group. The PNC and MISC groups are abnormal in 
almost all factors, but the mean values for the PBC, CA, and 
SC groups are normal. 
Factor VIII:C is not included in Table 5 because it was 
consistently normal or high (mean for 63 = 2.3 U Iml) in all 
patient categories. The one patient with hemophilia is excluded 
from this statement. 
Blood components used. Tables 6 and 7 show the mean 
number of units of red blood cells (RBC), fresh frozen plasma 
(FFP), platelets (Plat), and bags of cryoprecipitate (cryo) used 
during the operative procedures. For all 70 first transplants, 
the mean RBC used was 43 units, FFP 40 units, plat 21 units, 
and cryo 9 units. The range was very large for RBCs-from 3 
to 251. Figure 1 shows the wide distribution in numbers of 
TABLE 3. Coagulation abnormality points (CAS [means for each 
group]) 
No. patients Mean points Standard deviation Significance (P) 
PNC 20 5.3 1.2 <.0001 
Misc 10 4.8 2.0 <.001 
SC 8 2.8 1.9 <.05 
PBC 16 1.9 1.4 NS 
CA 10 0.8 0.8 
RBCs used. The median was 24 and the mean was 43 units of 
RBCs, indicating that the large numbers used in a few patients 
outweighed the lesser numbers in calculating the mean. Seven 
patients received over 100 units of red cells. Table 7 shows that 
the blood used in retransplantation is less than half that used 
in the first operation. 
This large blood component usage constituted a significant 
fraction of the total amount used in 1982 in Presbyterian-
University Hospital (550 beds), as shown in Table 8. 
Figure 2 shows the relationship between CAS and blood 
products used during the operation. There is little difference in 
TABLE 5. Mean values (U/m!) for coagulation factors for patients in 
each category and in the entire group 
Coagulation Factor 
Number in group 
II V VII IX X XI XII 
PNC 20 0.33 0.35 0.27 0.43 0.56 0.44 0.65 
Misc 10 0.46 0.45 0.52 0.45 0.64 0.46 0.67 
SC 8 1.13 0.64 1.42 1.02 1.43 0.63 1.00 
PBC 16 0.95 1.00 1.00 0.90 0.95 0.76 1.07 
CA 10 0.81 1.10 0.92 1.05 0.80 1.00 1.11 
Total 64 0.68 0.68 0.74 0.73 0.81 0.63 0.87 
Normal for all factors = 0.50-1.50 U/ml 
TABLE 6. Blood products usage during 70 first liver transplants 
(mean values for each disease category and for all patients 
No. patients RBC FFP Plat Cryo 
PNC 22 58.0 55.0 31.3 9.8 a 
Misc 11 43.7 42.1 23.0 12.5 
SC 8 58.1 47.6 21.6 24.3 
PBC 18 23.0 23.4 10.9 3.9 
CA 11 32.6 28.5 11.5 3.3 
All 70 42.8 39.9 20.5 9.3' 
a Excluding the hemophiliac. 
TABLE 7. Mean blood product usage in 17 retransplantations 
No. patients RBC FFP Plat Cryo 
PNC 2 8.5 8.0 21.5 6.0 
Misc 5 16.8 18.8 12.4 10.4 
SC 5 38.0 22.2 16.6 6.0 
PBC 5 11.6 9.0 9.8 2.4 
CA 0 0 0 0 0 
All 17 20.5 15.6 14.2 6.2 
TABLE 4. Mean values of coagulation tests and percentage of patients abnormal in each category and in the entire group 
Group No. TT (sec) (%) AT-III (V/ml) % APTT (sec) (%) Pit. Ct. PT I FSP (%) Lysis (%) (xl03M) (%) (sec) (%) (mg/dl) (%) 
PNC 20 30.3 (85) 36 (95) 40.9 (79) 92 (90) 16.8 (95) 182 (40) _a (25) -" (20) 
Misc 10 29.2 (80) 49 (90) 48.3 (80) 199 (70) 28.9 (80) 183 (50) _a (11) -" (33) 
SC 8 21.2 (63) 82 (50) 39.8 (75) 189 (63) 13.0 (25) 473 (0) o (0) o (0) 
PBC 16 21.7 (56) 94 (25) 35.7 (38) 249 (38) 12.3 (25) 389 (0) -" (13) 0 (0) 
CA 10 20.1 (55) 97 (22) 30.9 (10) 308 (0) 11.9 (0) 455 (0) o (0) 0 (0) 
ALL 64 25.3 (67) 67 (60) 39.0 (59) 188 (55) 16.3 (52) 313 (20) -" (13) -" (ll) 
~ormal 20 or < 70 or> 36.00r< 150 or> 13.50r< 150 or> 0 0 
, Mean values for + or 0 tests not meaningful. 
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FIGURE 1. Intraoperative RBCs used in 70 patients. Diagnosis: (M) 
miscellaneous; (B) primary biliary cirrhosis; (SC) sclerosing cholangi-
tis; (CA) tumor/cancer; and (PNC) postnecrotic cirrhosis. 
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TABLE 8. 1982 blood products used in Presbyterian-University 
Hospital and in 35 liver transplant patients 
Product 
RBC 
FFP 
Plat 
Cryo 
200 
150 
100 
50 
17,706 Patients 35 Patients (43 transplants) 
21,701 2768 
13,032 2752 
11,577 1908 
314 
() NUMBER OF PAT IENTS 
IIII.I!IIII ~~:q IttJ Ree 
234 567 
COAGULATION ABNORMALITY SCORE 
% 
13 
21 
16 
FIGURE 2. First liver transplants. Operative blood product used 
versus coagulation abnormality score in 64 patients. 
components used when the coagulation scores range from 4 to 
7. Only when the coagulation defects are minor (score 0-2), is 
the use of lesser amounts of blood components evident. 
Operative deaths. Nine patients died in the operating room 
(eight first transplants and one second transplant). The pre-
operative CAS· for the eight first transplants was 5.13, as 
compared with 3.15 for the 55 who survived the immediate 
?pera~ive period and for whom preoperative coagulation data 
1S avrulable. This is a significant difference at the P<.03 level. 
Looking at all 70 first transplants, the mean blood compo-
nent use in the eight operative deaths was significantly higher 
than.in the 62 operative survivals. RBC use was 107 units in 
the operative deaths and 34 units in the survivors FFP use was 
. 90 units vs. 33 units, and platelets were 35 units ~sK 19. The P 
~alues are <.001 for RBCs, <.001 for FFP, and <.07 for plate-
ets. Three of the seven patients who received more than 100 
units of RBCs at operation died during the operative period. 
Correlations of coagUlation abnormalities, blood components 
used during ope ratio.. CLc;d .c:. _ivaI. In the 64 patients with 
preoperative coagulation studies, the CAS, as correlated with 
RBC usage, showed a correlation coefficient of 0.454 (P=.OOl), 
and with survival it showed a correlation coefficient of -0.281 
(P<.02). Intraoperative RBC use in 70 first transplants corre-
lated with a survival gave a correlation coefficient of -0.408 
(P=.OOl). These correlations are still significant if the intra-
operative deaths are omitted. 
DISCUSSION 
The liver plays a central role in the maintenance of adequate 
hemostasis. Among its many functions are the synthesis and 
degradation of clotting factors I (fibrinogen), II (prothrombin), 
V, VII, IX, X, XI, XII, Fletcher, and Fitzgerald; clotting inhib-
itors alpha-I-antitrypsin, alpha-2-macroglobulin, antithrombin 
III; and plasminogen. Only F VIII is an exception: both F 
VIIIR:Ag and F VIIIR:vW are synthesized in vascular endothe-
lium, and the site of synthesis of F VIII:C is unknown. When 
parenchymal liver cells suffer widespread damage, as in post-
necrotic or Laennec's cirrhosis, fulminant hepatitis and long-
standing 0'1 antitrypsin deficiency, severe clotting abnormali-
ties are observed. When bile ducts are involved (PBC and SC) 
or malignancy is present, large areas of normal parenchymal 
tissue are still able to produce normal amounts of coagulation 
factors. These relationships held relatively true among our 
patient groups: The correlation between the degree of preop-
erative coagulation abnormality (CAS) and the amount of red 
cells transfused (used as a measure of bleeding) is fairly im-
pressive. For the eight intraoperative deaths during first trans-
plant, the mean CAS was significantly higher than that of the 
survivors. Blood use was also far greater in these patients. This 
suggests that immediate preoperative correction of the coagu-
lation defect by plasma exchange and platelet transfusions 
might be of significant benefit in patients with preoperative 
CAS's of 4 or more. 
Many factors influence the difficulty of the operation and 
the amount of bleeding. Previous surgery with scarring and 
shortening of vessels may make the operation next-to-impos-
sible. This partially explains the unusually large amount of 
blood used in cases of sclerosing cholangitis. Other factors that 
may contribute to excessive bleeding are intercurrent local 
infection, abnormalities of the vascular pattern (collaterals, 
etc.), or intake of drugs that interfere with hemostasis, such as 
aspirin or warfarin. 
Survival of the 70 patients with liver transplants was 46% 
for six months or longer. If the intraoperative period is ex-
cluded, deaths in the first six months after transplant were 
usually caused by infection or rejection, or both. After six 
months, recurrent disease or an unrelated cause were most 
often found. 
Survival has a strong negative correlation with the CAS and 
the numbers of RBC units used. Even with the elimination of 
operative deaths, there is still an inverse correlation between 
CAS and survival, particularly in the PNC group. This is hard 
to explain because the preoperative CAS would seem to have 
no bearing on the new liver unless the original disease is 
recurrent. The significance of RBC usage correlated with sur-
vival is much less if the intraoperative deaths are eliminated. 
Transfusions of large amounts of blood products greatly in-
crease the risk of transmission of a blood-borne infection such 
as non-A, non-B hepatitis or AIDS, although we have not 
recognized any in this group of liver transplant patients. Re-
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covery and re-use of the patient's own red cells is slow, and it 
would only reduce this risk by a small amount because FFP 
and platelets would still be necessary. 
The Central Blood Bank of Pittsburgh handles 130,000 units 
of blood annually,"such that the increase caused by the trans-
plants (about 2700 units per year) is only about 2%. However, 
the need is sufficiently episodic that continual vigilance in 
monitoring blood supply is required. Recovery and re-use of the 
patient's own blood cells from the operative site is tedious and 
has not significantly reduced the blood bank demand. The 
speed necessary to meet blood product demand during liver 
transplant procedures, which almost always occur at night and 
last 12-24 hr, has required an added technologist, additional 
clerical support, and a "runner" to deliver blood products to 
the operating room. Committed shipments of volunteer blood 
have eased the extra stress on the blood supply caused by the 
large numbers of patients for transplant and other surgical or 
medical procedures coming from geographical areas outside of 
our drawing area. 
This study has shown that widespread parenchymal liver 
damage, occurring in PNC, a1 antitrypsin deficiency, and ful-
minant hepatitis, is consistently associated with preoperative 
clotting abnormalities. The greater the abnormality, the greater 
the number oJ transfused red cells required during the opera-
tion. This suggests that immediate preoperative repair of the 
abnormalities might improve survival in these critically ill 
patients. 
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